免疫治疗药物nivolumab用于非小细胞肺癌治疗的研究进展

被引：7

作者：

潘峰

顾爱琴

王韡旻

姜丽岩

机构：

[1] 上海交通大学附属胸科医院呼吸内科

来源：

世界临床药物 | 2016年 / 37卷 / 10期

关键词：

nivolumab; 非小细胞肺癌; 免疫治疗; PD-1/PD-L1通路;

D O I：

10.13683/j.wph.2016.10.013

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100117 [系统生物医学];

摘要：

免疫介导肿瘤治疗是对传统肿瘤学观念的重大革新,也是肿瘤治疗技术的又一突破。免疫介导肿瘤治疗药物在抑制肿瘤细胞生长的同时对正常人体细胞影响甚微,以nivolumab为代表的程序性死亡受体1(PD-1)及其配体程序性死亡配体1(PD-L1)为靶点的免疫治疗药物,具有较好的疗效和耐受性,日益受到关注。本文综述nivolumab治疗非小细胞肺癌的研究进展。

引用

页码：717 / 720

页数：4

共 10 条

[1]

PD-1抑制剂新药nivolumab [J].

王莉 ;

张志叶 .

中国新药杂志, 2016, (09) :961-963

[2]

A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker [J].

Aguiar, Pedro N., Jr. ;

Santoro, Ilka Lopes ;

Tadokoro, Hakaru ;

Lopes, Gilberto de Lima ;

Filardi, Bruno Andraus ;

Oliveira, Pedro ;

Castelo-Branco, Pedro ;

Mountzios, Giannis ;

de Mello, Ramon Andrade .

IMMUNOTHERAPY, 2016, 8 (09) :1011-1019

[3]

The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer [J].

Tanvetyanon, Tawee ;

Creelan, Benjamin C. ;

Antonia, Scott J. .

EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (09) :903-910

[4]

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial [J].

Rizvi, Naiyer A. ;

Mazieres, Julien ;

Planchard, David ;

Stinchcombe, Thomas E. ;

Dy, Grace K. ;

Antonia, Scott J. ;

Horn, Leora ;

Lena, Herve ;

Minenza, Elisa ;

Mennecier, Bertrand ;

Otterson, Gregory A. ;

Campos, Luis T. ;

Gandara, David R. ;

Levy, Benjamin P. ;

Nair, Suresh G. ;

Zalcman, Gerard ;

Wolf, Juergen ;

Souquet, Pierre-Jean ;

Baldini, Editta ;

Cappuzzo, Federico ;

Chouaid, Christos ;

Dowlati, Afshin ;

Sanborn, Rachel ;

Lopez-Chavez, Ariel ;

Grohe, Christian ;

Huber, Rudolf M. ;

Harbison, Christopher T. ;

Baudelet, Christine ;

Lestini, Brian J. ;

Ramalingam, Suresh S. .

LANCET ONCOLOGY, 2015, 16 (03) :257-265

[5]

Nivolumab for the treatment of cancer [J].

Gunturi, Anasuya ;

McDermott, David F. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (02) :253-260

[6]

B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer: Current Status and Future Direction.[J].Scott Gettinger;Roy S. Herbst.The Cancer Journal.2014, 4

[7]

Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation [J].